Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 10,492 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Peanut Allergy
Interventions: VLP Peanut, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more

Conditions: Primary Immune Deficiency
Interventions: Newnorm; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more

Conditions: Perimenopause, Vasodilation, Estrogen
Interventions: Estradiol (mylan or vivelle dot patch), Placebo; Drug · Other
Lead sponsor: University of Delaware; Other
Eligibility: 40 Years to 58 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Kidney Disease, Chronic
Interventions: BI 690517, Placebo matching BI 690517, Empagliflozin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 8,371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 53
States / cities: Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more

Conditions: Neurofibromatosis 1, Neurofibromatosis Type 1, NF1, Neurofibroma, Plexiform
Interventions: AZD6244; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2032
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Cincinnati, Ohio + 1 more

Conditions: Spinal Cord Injuries, Pain, Chronic, Spinal Cord Injury, Acute
Interventions: Hypnosis enhanced cognitive behavioral therapy, Pain Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 16 Years to 85 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Desmoid, Desmoid Tumor
Interventions: AL102, Placebo; Drug · Other
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 23
States / cities: Pheonix, Arizona • Duarte, California • Santa Monica, California + 17 more

Conditions: Brain Cancer
Interventions: Fluorescein, Fluorescein + ALA; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Duchenne Muscular Dystrophy
Interventions: AAV8 DetectCDx; Diagnostic Test
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 0 Years to 25 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Patent Ductus Arteriosus, Congenital Heart Disease
Interventions: Near Infrared Spectroscopy; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 1 Minute to 7 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hip Injuries, Tendon Injuries, Orthopedic Procedures
Interventions: Standard gluteus medius repair with Tapestry Biointegrative implant; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Columbus, Ohio • Westerville, Ohio

Conditions: Osteosarcoma, Osteosarcoma Recurrent
Interventions: Olaparib, Ceralasertib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 12 Years to 40 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Dentatorubral-Pallidoluysian Atrophy
Interventions: nL-ATN1-002; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 17 Years to 17 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more

Conditions: Type 1 Diabetes
Interventions: FAMS-T1D, Digital resources for diabetes; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 24 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Salt Lake City, Utah

Conditions: Parkinson Disease, Dysarthria
Interventions: Remote speech rehabilitation; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 25 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: HIV-1-infection
Interventions: ISL/LEN, B/F/TAF, PTM B/F/TAF, PTM ISL/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Palmidrol, Placebo Administration, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Middletown, Connecticut • Urbana, Illinois • Sioux City, Iowa + 7 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Litifilimab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more

Conditions: Breast Cancer
Interventions: educational intervention, questionnaire administration, counseling intervention, survey administration, quality-of-life assessment; Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions: AROMHA Longitudinal Smell Test; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Pazopanib, Temozolomide, Trabectedin, Transthoracic Echocardiography Test; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 144
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more

Conditions: Sleep-Disordered Breathing, Sleep Architecture, Arrhythmia
Interventions: Belun Ring, Belun Cor; Device
Lead sponsor: Belun Technology Company Limited; Other
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Chardon, Ohio • Cleveland, Ohio

Search by objective public record fields.

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Impact of Estradiol on Endothelial Function in Peri-Menopausal Women

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Hypnotic Cognitive Therapy Reduce Acute & Chronic SCI Pain in Inpatient Rehabilitation

A Study of AL102 in Patients With Progressing Desmoid Tumors

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD

PDA for Kidneys Study

Evaluation of Healing Following Open Gluteus Medius Repair With Biointegrative Implant

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

Dysarthria Management for Minor Groups

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Validation of Belun Ring Gen3 Deep Learning Algorithms With Subxiphoid Body Sensor